Skip to main content
LIFECORE BIOMEDICAL, INC. \DE\ logo

LIFECORE BIOMEDICAL, INC. \DE\ — Investor Relations & Filings

Ticker · LFCR ISIN · US5147661046 LEI · 549300EHBZ5OM9ND9O43 US Manufacturing
Open in API
Filings indexed 1,096 across all filing types
Latest filing 2020-01-02 Board/Management Inform…
Country US United States of America
Listing US LFCR

About LIFECORE BIOMEDICAL, INC. \DE\

https://www.lifecore.com/

Lifecore Biomedical is an integrated contract development and manufacturing organization (CDMO) that specializes in sterile injectable pharmaceutical drug products and medical devices. The company provides a full range of services, including specialty formulation, process development, aseptic filling, and final packaging, supporting products from clinical phases through to commercial supply. A key area of expertise is the handling of complex and highly viscous formulations. In addition to its CDMO capabilities, Lifecore is a primary producer of non-animal-sourced sodium hyaluronate (hyaluronic acid), offering it in various molecular weights and formats, including bulk material, hydrogels, and filled syringes and vials for diverse applications.

Recent filings

Filing Released Lang Actions
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The content includes a press release about financial results for the second quarter of fiscal 2020, restructuring and cost-saving actions, and changes in senior management including CFO resignation and appointment. The document also references attached press releases as exhibits. The key elements are the announcement of financial results and management changes. Since the document is primarily an 8-K current report announcing financial results and management changes, and includes a press release of financial results (not the full financial report itself), the best classification is 'Call Transcript' (CT) is not appropriate as this is not a transcript. It is not a full Annual or Interim Report. It is not a simple earnings release (ER) because it is a current report with multiple items including management changes. The management changes are significant and detailed, so the best fit is 'Board/Management Information' (MANG) because it announces changes in senior management and board-related information. The financial results announcement is secondary and presented as a press release exhibit, not the full report. Therefore, the primary classification is MANG with high confidence.
2020-01-02 English
FORM 4
Director's Dealing
2019-11-14 English
LANDEC CORP
Major Shareholding Notification
2019-11-08 English
FORM 4
Director's Dealing
2019-11-06 English
FORM 4
Director's Dealing
2019-11-05 English
FORM 4
Director's Dealing
2019-11-01 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.